Sertraline (Zoloft)

Sertraline — Zoloft — is the most prescribed antidepressant in the United States. That fact alone is worth pausing on. Out of all the SSRIs, all the SNRIs, all the atypicals, the one that wins by volume is sertraline. It wins not because of any single dramatic advantage but because it sits in a quiet sweet spot of tolerability, breadth, and safety that no other agent quite matches.

The pharmacology is clean. Sertraline blocks SERT, like all SSRIs. It has weak DAT inhibition at higher doses — measurable in vitro, probably not clinically meaningful for most patients. It has modest sigma-1 receptor activity that some have hypothesized contributes to its anxiety effects. The half-life is about twenty-six hours, which means once-daily dosing with smooth steady-state and modest discontinuation syndrome — not as forgiving as fluoxetine, not as harsh as paroxetine.

What makes sertraline the workhorse is the breadth and the safety. The FDA approvals span major depression, OCD, panic disorder, PTSD, social anxiety disorder, and PMDD. Few other antidepressants cover this range. The drug interactions are minimal — sertraline has only weak CYP inhibition compared to fluoxetine or paroxetine — so it plays well with other medications, which matters more than it sounds when your patient is on five drugs from three other prescribers.

The pregnancy and lactation data is the differentiator. Among SSRIs, sertraline has the most extensive safety record in pregnancy and the lowest concentrations in breast milk. The pregnancy registries, accumulated over decades, do not show a clear teratogenic signal. The lactation studies show infant exposure that is consistently very low. When a patient is pregnant or breastfeeding and an SSRI is clinically needed, sertraline is the agent reached for. This is the single most useful piece of information about sertraline.

Side effects follow the SSRI class. The GI complaints — particularly diarrhea, which is somewhat more prominent with sertraline than other SSRIs — emerge in the first two to four weeks and usually settle. Sexual dysfunction at the full therapeutic dose is in the 30-50% range, which patients should hear about before the prescription, not after. Sweating, modest weight changes over time, occasional sleep disturbance, occasional jitteriness. The discontinuation syndrome exists but is more manageable than paroxetine or venlafaxine.

Start at 25 to 50 milligrams. Target dose for most adults is 50 to 200 milligrams. The titration schedule is generally one to two weeks at the starter dose, then move up. Patients with anxiety disorders often need a slower start — 25 milligrams for a week, sometimes longer — because the activation early can amplify the anxiety they came to treat.

Sertraline is the unflashy answer in psychopharmacology. It is rarely the most exciting choice. It is, more often than not, the right one.